Importer of Controlled Substances Application: Noramco Inc., 53107-53108 [2018-22832]
Download as PDF
<![CDATA[
53107
Federal Register / Vol. 83, No. 203 / Friday, October 19, 2018 / Notices
The DEA has considered the factors in
21 U.S.C. 823(a) and determined that
the registration of this registrant to
manufacture the applicable basic classes
of controlled substances is consistent
with the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated the company’s maintenance
of effective controls against diversion by
inspecting and testing the company’s
physical security systems, verifying the
company’s compliance with state and
local laws, and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the DEA has granted a
Dated: October 10, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–22829 Filed 10–18–18; 8:45 am]
The
companies listed below applied to be
registered as importers of various basic
classes of controlled substances.
Information on previously published
notices are listed in the table below. No
comments or objections were submitted
and no requests for hearings were
submitted for these notices.
SUPPLEMENTARY INFORMATION:
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Registration
ACTION:
Registrants listed below have
applied for and been granted
registration by the Drug Enforcement
Administration (DEA) as importers of
various classes of schedule I or II
controlled substances.
SUMMARY:
Notice of registration.
Company
FR Docket
Published
Chattem Chemicals, Inc ..........................................................................................................................................
83 FR 39129 ..
Myoderm .................................................................................................................................................................
83 FR 39130 ..
Mylan Pharmaceuticals, Inc ....................................................................................................................................
Anderson Brecon, Inc .............................................................................................................................................
83 FR 22517 ..
83 FR 39128 ..
August 8,
2018.
August 8,
2018.
May 15, 2018.
August 8,
2018.
The DEA has considered the factors in
21 U.S.C. 823, 952(a) and 958(a) and
determined that the registration of the
listed registrants to import the
applicable basic classes of schedule I or
II controlled substances is consistent
with the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated each company’s
maintenance of effective controls
against diversion by inspecting and
testing each company’s physical
security systems, verifying each
company’s compliance with state and
local laws, and reviewing each
company’s background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the DEA has
granted a registration as an importer for
schedule I or II controlled substances to
the above listed companies.
Dated: October 10, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–22830 Filed 10–18–18; 8:45 am]
amozie on DSK3GDR082PROD with NOTICES1
registration as a bulk manufacturer to
the above listed company.
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Noramco Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before November 19, 2018. Such
persons may also file a written request
for a hearing on the application on or
before November 19, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearings
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
DATES:
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
Comments and requests for hearings on
applications to import narcotic raw
material are not appropriate. 72 FR
3417, (January 25, 2007).
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on July 4,
2018, Noramco Inc., 1550 Olympic
Drive, Athens, Georgia 30601 applied to
be registered as an importer of the
following basic classes of controlled
substances:
Controlled substance
Drug code
Marihuana Extract ...........................................................................................................................................................
VerDate Sep<11>2014
17:25 Oct 18, 2018
Jkt 247001
PO 00000
Frm 00081
Fmt 4703
Sfmt 4703
E:\FR\FM\19OCN1.SGM
19OCN1
7350
Schedule
I
53108
Federal Register / Vol. 83, No. 203 / Friday, October 19, 2018 / Notices
Controlled substance
Drug code
Marihuana ........................................................................................................................................................................
Tetrahydrocannabinols ....................................................................................................................................................
Nabilone ...........................................................................................................................................................................
Phenylacetone .................................................................................................................................................................
Thebaine ..........................................................................................................................................................................
Poppy Straw Concentrate ...............................................................................................................................................
Tapentadol .......................................................................................................................................................................
The company plans to import
phenylacetone (8501), and poppy straw
concentrate (9670) to bulk manufacture
other controlled substances for
distribution to its customers. The
company plans to import an
intermediate form of tapentadol (9780)
to bulk manufacture tapentadol (9780)
for distribution to its customers.
The company plans to import
impunities of buprenorphine that have
been determined by DEA to be captured
under drug code (9333) thebaine.
In reference to drug codes 7360 and
7370, the company plans to import a
synthetic cannabidiol and a synthetic
tetrahydrocannabinol. No other activity
for these drug codes is authorized for
this registration. Placement of these
drug codes onto the company’s
registration does not translate into
automatic approval of subsequent
permit applications to import controlled
substances. Approval of permit
applications will occur only when the
registrant’s business activity is
consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization
will not extend to the import of FDA
approved or non-approved finished
dosage forms for commercial sale.
Dated: October 10, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–22832 Filed 10–18–18; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Fisher Clinical Services,
Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before November 19, 2018. Such
persons may also file a written request
for a hearing on the application on or
before November 19, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
DATES:
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on June 4,
2018, Fisher Clinical Services, Inc.,
7554 Schantz Road, Allentown,
Pennsylvania 18106 applied to be
registered as an importer of the
following basic class of controlled
substance:
SUPPLEMENTARY INFORMATION:
Drug code
Psilocybin .........................................................................................................................................................................
The company plans to import the
listed controlled substance for clinical
trials.
DEPARTMENT OF JUSTICE
Dated: October 10, 2018.
John J. Martin,
Assistant Administrator.
Agency Information Collection
Activities; Proposed eCollection
eComments Requested; Revision of a
Currently Approved Collection;
Comments Requested: 2019 School
Crime Supplement (SCS) to the
National Crime Victimization Survey
(NCVS)
amozie on DSK3GDR082PROD with NOTICES1
BILLING CODE 4410–09–P
Bureau of Justice Statistics,
Department of Justice.
ACTION: 30-Day notice.
AGENCY:
VerDate Sep<11>2014
17:25 Oct 18, 2018
Jkt 247001
PO 00000
Frm 00082
Fmt 4703
Sfmt 4703
7437
Schedule
I
The Department of Justice
(DOJ), Office of Justice Programs,
Bureau of Justice Statistics, will be
submitting the following information
collection request to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995.
DATES: Comments are encouraged and
will be accepted for 30 days until
November 19, 2018.
FOR FURTHER INFORMATION CONTACT: If
you have additional comments
especially on the estimated public
burden or associated response time,
SUMMARY:
[OMB Number 1121–0184]
I
I
II
II
II
II
II
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
Controlled substance
[FR Doc. 2018–22828 Filed 10–18–18; 8:45 am]
7360
7370
7379
8501
9333
9670
9780
Schedule
E:\FR\FM\19OCN1.SGM
19OCN1
]]>Agencies
[Federal Register Volume 83, Number 203 (Friday, October 19, 2018)]
[Notices]
[Pages 53107-53108]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-22832]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Noramco Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before November 19, 2018.
Such persons may also file a written request for a hearing on the
application on or before November 19, 2018.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for hearings should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152. Comments and requests for hearings on
applications to import narcotic raw material are not appropriate. 72 FR
3417, (January 25, 2007).
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.34(a), this is notice that on July
4, 2018, Noramco Inc., 1550 Olympic Drive, Athens, Georgia 30601
applied to be registered as an importer of the following basic classes
of controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Marihuana Extract.................. 7350 I
[[Page 53108]]
Marihuana.......................... 7360 I
Tetrahydrocannabinols.............. 7370 I
Nabilone........................... 7379 II
Phenylacetone...................... 8501 II
Thebaine........................... 9333 II
Poppy Straw Concentrate............ 9670 II
Tapentadol......................... 9780 II
------------------------------------------------------------------------
The company plans to import phenylacetone (8501), and poppy straw
concentrate (9670) to bulk manufacture other controlled substances for
distribution to its customers. The company plans to import an
intermediate form of tapentadol (9780) to bulk manufacture tapentadol
(9780) for distribution to its customers.
The company plans to import impunities of buprenorphine that have
been determined by DEA to be captured under drug code (9333) thebaine.
In reference to drug codes 7360 and 7370, the company plans to
import a synthetic cannabidiol and a synthetic tetrahydrocannabinol. No
other activity for these drug codes is authorized for this
registration. Placement of these drug codes onto the company's
registration does not translate into automatic approval of subsequent
permit applications to import controlled substances. Approval of permit
applications will occur only when the registrant's business activity is
consistent with what is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the import of FDA approved or non-
approved finished dosage forms for commercial sale.
Dated: October 10, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018-22832 Filed 10-18-18; 8:45 am]
BILLING CODE 4410-09-P
